6 min. read

32 Pear patents. Amwell $644M IPO.

Issue 069

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about how "breakthrough" is "too breakthrough" to secure CMS reimbursement under its latest proposed rule. Plus -- continuing on the "break" theme -- I posted the numbers related to Teladongo merger break-up fees. Finally, I dug into how some think about the regulated and unregulated

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles